Accurate HER2 assessment in breast cancer is essential for guiding targeted therapy, yet traditional visual scoring is challenging. The updated ASCO/CAP reporting template adds HER2-null, ultra-low, and low categories, increasing interpretation complexity. This study evaluates an AI-based algorithm (HER2 APP) for precise, efficient quantification of HER2 membrane positivity in 422 digitized biopsies.

Xu Xuan Lim¹, Diego F. Sanchez^2,3, Thomas W. Ramsing⁴, Anders B. Jensen⁴, Jeppe Thagaard⁴, Angela Cramer¹, Pedro Oliveira¹

1. The Christie NHS Foundation Trust
2. Cancer Research UK – Manchester Institute
3. MCRC
4. Visiopharm